siderably lower than that observed in age-and sex-matched NOD-scid mice or young prediabetic NOD mice Ewhich are estimated to have Q2000 islets per NOD mouse (5)^. The average diameter of the islets from Rx-NOD mice was 5.2 T 0.1 times as large as that of age-matched NOD-scid mice (Fig. 1 , C, D, and F; P G 0.05). This increase in islet size was due not to hypertrophy of individual b cells but to increased numbers of b cells and not of glucagon-expressing a cells ( fig. S2 ). We estimated that the total b cell volume in the Rx-NOD mice was 22.5 T 4.1% of that of age-matched NOD-scid mice. Similarly low numbers (12.2 T 1.7) of significantly enlarged islets (P G 0.05) were observed in age-matched NOD mice that failed to develop spontaneous diabetes (Fig. 1, D to F) .
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To determine whether the b cells in the Rx-NOD were of host origin or derived from donor spleen cells, we examined all the Rx-NOD islets for expression of GFP. No b cells expressing GFP were detected in any of the islets examined ( Fig. 1 , G and H) or in the organs outside of the pancreas. Thus, our data do not support a conclusion of b cell regeneration from spleenderived stem cells. All the hyperplastic islets from the five cured Rx-NOD mice were associated with circumferentially distributed lymphocytes (peri-insulitis) of donor origin ( fig. S3 ) and devoid of invasive insulitis. The majority of these peri-islet lymphocytes were CD4 þ CD25 þ cells, with a small portion expressing the transcriptional factor FoxP3 þ ( fig.   S3 ) (6) . These observations suggest that regulatory T cells may function to control autoimmunity locally where b cells are situated. The islets that stained very weakly or did not stain for insulin in the one Rx-NOD mouse without hyperplasia did not have a notable peri-islet lymphocytic infiltrate.
The finding that autoimmune diabetes in NOD mice can be reversed by a complex protocol combining islet transplantation, FCA treatment, and transfer of semi-allogeneic splenocytes suggests a potential for novel b cell replacement therapies for human T1DM (2, 7). We confirmed these observations and demonstrated restoration of diabetic NOD mice to normoglycemia with this therapeutic protocol. We did not observe b cell reconstitution from the infused spleen cells, and these studies were not designed to determine whether the observed host-derived b cells were the result of replication of preexisting b cells or differentiation from stem-cell precursors. Our studies indicate that normoglycemia in Rx-NOD mice can be maintained by a very low number of hyperplastic islets or, in one case, by weakly insulinpositive or insulin-negative islets surviving the autoimmunity. The consistent association between islet hyperplasia and peri-insulitis (8, 9) suggests a hypothesis that autoreactivity, when restrained by regulatory T cells, may facilitate the development of islet hyperplasia. The limited b cell mass required to maintain normoglycemia in this model contrasts with the large numbers of transplanted islets required to maintain normal glycemia (1, 10) . Our studies confirm that autoimmune diabetes can be reversed and that sufficient endogenous b cell mass can be restored to cure diabetic NOD mice with the treatment protocol developed by Faustman and colleagues (2, 7) . Translating these findings into therapies useful for curing T1DM in humans remains a challenge. A cure for type 1 diabetes will probably require the provision or elicitation of new pancreatic islet b cells as well as the reestablishment of immunological tolerance. A 2003 study reported achievement of both advances in the NOD mouse model by coupling injection of Freund's complete adjuvant with infusion of allogeneic spleen cells. It was concluded that the adjuvant eliminated anti-islet autoimmunity and the donor splenocytes differentiated into insulin-producing (presumably b) cells, culminating in islet regeneration. Here, we provide data indicating that the recovered islets were all of host origin, reflecting that the diabetic NOD mice actually retain substantial b cell mass, which can be rejuvenated/regenerated to reverse disease upon adjuvantdependent dampening of autoimmunity.
T ype 1 diabetes, an autoimmune disease that targets pancreatic islet b cells, is an important and increasing health problem. It is generally believed that effective therapy for autoimmune diabetes will require two scientific advances: (i) restoration of insulin production by providing or eliciting new b cells, and (ii) repair of the breakdown in immunological tolerance that precipitated the disease in the first place.
Recently, successful achievement of both of these advances was reported, culminating in disease abrogation in a fraction of severely diabetic NOD mice (1), a widely used murine model of the human type 1 disorder. The protocol incorporated injection of a single dose of Freund_s complete adjuvant (FCA) into severely diabetic mice, coupled with repeated infusion of allogeneic splenocytes, resulting in restoration of normoglycemia and permanent disease extinction. The conclusion of this study was that the FCA had eliminated anti-islet autoimmunity and that the donor splenocytes had differentiated into insulin-producing (presumably b) cells, ultimately leading to islet regeneration.
Although FCA has been used for a number of years in a variety of experimental protocols to modulate diabetes in NOD mice (2, 3), the concept of donor splenocytes giving rise to islets in a host pancreas was a novel and exciting one, prompting the suggestion that the function of the spleen should be radically reappraised to include a role as a reservoir of multilineage stem cells (4). We set out to further dissect the underlying mechanisms of diabetes reversal by this treatment regime.
As a first step, we attempted to replicate the original findings, following closely the protocol published by Kodama et rating additional details from more extensive protocols provided by the authors (5). Severely diabetic NOD mice (blood glucose 9400 mg/dl) were transplanted under the kidney capsule with syngeneic islets in order to maintain insulin levels; engraftment was deemed a failure when hyperglycemia reappeared before 2 days. Thirty successfully transplanted mice were injected with FCA and infused with live allogeneic EC57BL/6 Â Balb/c (referred to as CB6 F1)^splenocytes (Table 1 ). The majority (21 of 30) developed diabetes before the end of the 120-day observation period (2 to 60 days after islet transfer). We do not know why the 70% reversion rate observed here was higher than the 8% reported by Kodama et al. (1) . After removal of the transplanted islets from the nine mice that had completed the 120-day observation period, four animals became diabetic shortly thereafter, indicating that the insulin that permitted their survival prenephrectomy was produced mainly by the grafted islet cells. The other five animals remained normoglycemic to termination, indicating that they carried insulin-producing cells outside the islet graft, which the immune system no longer destroyed. This 56% of longterm survivors that were insulin-self-sufficient was similar to the 67% reported by Kodama et al. (1) .
Histology of the pancreas revealed islets of various sizes ( fig. S1A) , including a hyperplastic subset found in both the Bcured[ and Brevertant[ long-term survivors, although more frequent in the former (e.g., fig. S1B ). All mice had insulitis ( fig. S1, A to D) as well as some islets free of S1 , A and E). Many islets exhibited an innocuous-looking infiltrate like that described in a number of contexts wherein insulitis does not progress to overt diabetes (6). Indeed, there was a striking similarity to the islets of recentonset diabetic NOD mice treated with anti-CD3 monoclonal antibody (mAb) ( fig. S1F ).
Insulitis was also observed in the syngeneic islet graft ( fig. S1G ).
We next evaluated the possibility that pancreatic islets were regenerated through differentiation of donor splenocytes. Because the fluorescence in situ hybridization (FISH) assays used in the previous study (1) can be challenging and their results can be equivocal, we established a more robust test based on singlenucleotide polymorphism (SNP) analysis of DNA derived from islet tissue isolated from histological sections by laser-capture microdissection (LCM). Islet tissue and any associated inflammation could be definitively identified by staining sections with hematoxylin and/or antiinsulin mAb (Fig. 1A) and could be cleanly excised (Fig. 1B) . The SNP analysis assessed three polymorphic loci on three separate chromosomes (Fig. 1C) and clearly distinguished cells of NOD and CB6 F1 origin. In all Bcured[ animals tested, all tissue was derived from NOD host or graft cells; none came from CB6 F1 donor splenocytes (Fig. 1D) .
This result is actually the expected one, given that the NOD host should make a strong alloresponse to the splenocytes_ large major histocompatibility complex (MHC) divergence
, and A b in the CB6 F1s). We found no evidence of chimerism in the spleen or lymph nodes subsequent to the splenocyte infusions ( fig. S2) . Instead, strong alloreactivity was evident from the development of antibodies to the allogeneic splenocytes at titers up to 1/5000 (7).
The fleeting presence of the splenocytes raised the possibility that the protocol_s beneficial effects might derive primarily from the FCA injection. This adjuvant is known to have immunomodulatory effects in the NOD context (2, 3), but a FCA-alone control was not included in the report by Kodama et al. (1) . Therefore, under otherwise the same protocol, we treated 13 severely diabetic NOD mice with FCA and a syngeneic islet transplant but not with allogeneic splenocytes. Four of these animals maintained normal glucose levels during the 120-day observation period, and three of these remained normoglycemic after removal of the transplanted islets (table S1) .
A likely source of the insulin that permitted certain long-term survivors to remain nondiabetic is residual islets that expanded through either differentiation or replication once autoimmunity had been muted. Such a scenario is consistent with recent reports that substantial b cell mass can be detected in diabetic NOD mice (8) . To test this notion, we performed a morphometric analysis of pancreatic b cell mass both in the prediabetic state (n 0 3) and in the first weeks after the development of severe hyperglycemia (n 0 23). Residual b cell mass was detected in essentially all of the diabetic mice ( fig. S3 ), although it was variable in quantity and was always diminished relative to that of prediabetic comparators. There was no correlation between the blood glucose value and residual b cell mass (9) . These results indicate that host b cells can contribute to islet regeneration promoting disease reversal in severely diabetic NOD mice.
Our experiments, like those of Kodama et al. (1) , yielded a fraction of previously diabetic NOD mice that survived for a long term after syngeneic islet transplantation, a proportion of which remained normoglycemic even after the removal of the grafted islets. On the other hand, we found no evidence that the source of insulin underlying the reversal of diabetes was islet cells derived from donor splenocytes. Rather, we found that the diabetic hosts had substantial residual b cell mass and that the recovered/ expanded islets were all of NOD origin rather than splenocyte CB6 F1 origin. Our conclusions match very well those of two accompanying reports (10, 11) . Given recent reports of active b cell replication in both nondiabetic (12) and diabetic (8) states, the most likely explanation for islet recovery in this context is that the dampening of autoimmunity permitted b cell replication to outdo b cell death. However, other explanations remain possible: differentiation of new host b cells or seeding and expansion of islet graft-derived cells (also of NOD genotype).
Should the autonomous efficacy of FCA demonstrated in our study prompt a reconsideration of the use of the analogous reagent Bacille Calmette-Gu2rin (BCG), in isolation, to treat diabetic humans? Although a preliminary study with 17 newly diagnosed individuals appeared to show some therapeutic efficacy (13) , three more extensive, double-blind trials failed to demonstrate a positive effect (14) . Likely explanations for the divergent outcomes are simply that FCA and BCG are different reagents, or that the footpad injection of FCA Table 1 ). Nucleotides detected for three different SNP positions (rs4223216, rs4230624, and rs4151928) in microdissected islets are shown, with the corresponding nucleotides for control NOD and F 1 DNA (x, unsuccessful amplification; n.d., not done).
used for mice and the subcutaneous injection of BCG applied to humans are radically different interventions, the former provoking a massive systemic inflammatory response (15) difficult to contemplate for human patients.
